Clinical trial end points for high-grade glioma: the evolving landscape Article

Reardon, David A, Galanis, Evanthia, DeGroot, John F et al. (2011). Clinical trial end points for high-grade glioma: the evolving landscape . NEURO-ONCOLOGY, 13(3), 353-361. 10.1093/neuonc/noq203

Open Access International Collaboration

cited authors

  • Reardon, David A; Galanis, Evanthia; DeGroot, John F; Cloughesy, Timothy F; Wefel, Jeffrey S; Lamborn, Kathleen R; Lassman, Andrew B; Gilbert, Mark R; Sampson, John H; Wick, Wolfgang; Chamberlain, Marc C; Macdonald, David R; Mehta, Minesh P; Vogelbaum, Michael A; Chang, Susan M; Van den Bent, Martin J; Wen, Patrick Y

sustainable development goals

authors

publication date

  • March 1, 2011

published in

keywords

  • COGNITIVE FUNCTION
  • Clinical Neurology
  • GLIOBLASTOMA-MULTIFORME
  • Life Sciences & Biomedicine
  • MALIGNANT GLIOMAS
  • NEUROCOGNITIVE FUNCTION
  • Neurosciences & Neurology
  • Oncology
  • PHASE-II TRIAL
  • PROGNOSTIC-FACTORS
  • PROGRESSION-FREE SURVIVAL
  • QUALITY-OF-LIFE
  • RESPONSE ASSESSMENT
  • Science & Technology
  • TUMOR PROGRESSION
  • clinical trials
  • end point
  • malignant glioma

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 353

end page

  • 361

volume

  • 13

issue

  • 3